| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP3611-5mg | 5mg | $260.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
209.1200
5.1293
4.7095
.0137
2.4104
6.5793
Low
95.2364
4.5798
No
No
Yes
No
Yes
Yes
0.0
Yes
No
Yes
No
The discovery and development of antimicrobial drugs have always been a key focus of modern pharmaceutical research, especially in addressing infections caused by resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA). As an important clinically resistant pathogen, MRSA poses a serious challenge to global public health. Its infection is difficult to treat and has a high recurrence rate, urgently requiring the development of novel antimicrobial drugs. Natural products, due to their structural diversity and broad biological activity, have become important resources for antimicrobial drug development. In recent years, mulberry plants, as traditional medicinal plants, have been found in root extracts containing various natural compounds with potential pharmacological activity.
Multicaulisin is a Diels-Alder adduct recently isolated from the roots of mulberry trees of the genus Mulberry, demonstrating significant antibacterial activity, especially effective in inhibiting MRSA isolates. In addition to its antibacterial activity, Multicaulisin also exhibits anti-inflammatory effects, targeting various inflammation-related molecules such as IL-6, STAT3, CASP1, and TRPV1, indicating broad research and application prospects in anti-infective and inflammatory regulation. This article will systematically review the chemical structure and physicochemical properties of Multicaulisin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and explore its clinical application prospects.
Multicaulisin (CAS No.: 286461-76-5) is a typical Diels-Alder addition product with a molecular weight of 692.7170, classified as a high molecular weight natural product. Its structure incorporates multiple ring-like structures, reflecting a complex three-dimensional conformation, a structural feature that forms the basis for its biological activity. According to physicochemical data, the partition coefficient LogP value of Multicaulisin is 5.1293, indicating high lipid solubility, which may affect its in vivo distribution and cell membrane penetration ability. The polar surface area (TPSA) is 209.1200, and higher TPSA is usually associated with lower cell membrane permeability, which corresponds to its low water solubility (0.0137 mg/mL), suggesting that its solubility and bioavailability in vivo may be limited.
Additionally, Multicaulisin lacks blood-brain barrier penetration capability, and hERG channel inhibition tests yield negative results, indicating a low risk of cardiotoxicity. The Ames test result was 0.0, indicating no significant genotoxicity. These druggability parameters provide a preliminary basis for the safety evaluation of Multicaulisin.
Multicaulisin was first obtained from the root part of the mulberry tree (Morus spp.), a plant of the genus Mulberry. As a traditional important medicinal plant in China and East Asia, mulberry roots contain abundant secondary metabolites, including flavonoids, phenylpropanins, and various cyclic adducts. Multicaulisin is a new type of Diels-Alder additive, characterized by a unique structure and significant activity.
During extraction, organic solvents (such as ethanol and methanol) are typically used to extract mulberry roots, followed by multi-step separation and purification techniques such as liquid-liquid partitioning and column chromatography (silica gel column, reversed-phase C18 column), combined with high-performance liquid chromatography (HPLC) for purity detection and component analysis. Structural identification relies on various modern analytical methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), infrared spectroscopy (IR), and ultraviolet spectroscopy (UV). In recent years, with advances in separation technology, extraction efficiency and purification levels have improved significantly, laying the foundation for multi-volume preparation and pharmacological research.
Multicaulisin exhibits inhibitory effects on various bacteria, especially sensitive to Gram-positive bacteria represented by methicillin-resistant Staphylococcus aureus (MRSA). In vitro antimicrobial experiments showed that Multicaulisin significantly reduced MRSA's colony-forming unit (CFU) by inhibiting bacterial growth and reproduction, and its minimum inhibitory concentration (MIC) was competitive among similar natural products. Compared to traditional antibiotics, Multicaulisin showed better activity against resistant strains, suggesting it may exert effects through mechanisms different from conventional antibiotics.
The inflammatory response is a crucial component of the host's defense during bacterial infection. Multicaulisin demonstrates effective anti-inflammatory effects by regulating various inflammation-related molecules. In vitro cell models and animal experiments have shown that Multicaulisin can significantly reduce the expression of pro-inflammatory factors IL-6 and TNF-α, inhibit activation of STAT3 and NF-κB signaling pathways, and decrease CASP1-mediated inflammasome activity. Additionally, Multicaulisin's regulatory effects on TRPV1 and TRPA1 plasma channels may be involved in relieving inflammatory pain. Its effects on NOS2 and PTGS1/2 further demonstrate their multi-target role in regulating the synthesis of inflammatory mediators.
Although current research on Multicaulisin mainly focuses on antibacterial and anti-inflammatory properties, its complex chemical structure and multi-target effects suggest it may possess broader biological activities, such as antioxidant and immunomodulatory functions, and future research is expected to further explore its potential.
The antimicrobial mechanism of Multicaulisin is not yet fully understood, but it is speculated that it may achieve antibacterial effects by interfering with bacterial cell wall synthesis, membrane structural integrity, or key enzyme activity. Combined with its MRSA inhibitory activity, Multicaulisin may target bacterial resistance-related proteins or signaling pathways, blocking bacterial resistance mechanisms.
In terms of anti-inflammatory effects, Multicaulisin plays a role by regulating inflammatory signaling pathways through multiple targets. Its inhibitory effect on IL-6 and TNF-α reduces the release of inflammatory mediators and lowers the cascade amplification of inflammatory responses. STAT3 and NF-κB are key transcription factors for inflammatory signals, and Multicaulisin blocks the expression of inflammatory genes by inhibiting their activity. CASP1, as the core enzyme of the inflammasome, has reduced activity that reduces the maturation and release of pro-inflammatory cytokines. Regulation of TRPV1 and TRPA1 ion channels helps alleviate inflammation-related pain and neuroinflammatory responses. Regulation of PTGS1/2 and NOS2 affects the synthesis of prostaglandins and nitric oxide, further modulating the inflammatory environment.
In summary, Multicaulisin demonstrates its combined antibacterial and anti-inflammatory pharmacological properties through synergistic effects across multiple targets and pathways, providing a theoretical basis for the development of novel anti-infective drugs.
The druggability parameters of Multicaulisin show that it has a large molecular weight and high lipid solubility, but low water solubility, which may limit its oral bioavailability and in vivo distribution. A high TPSA value suggests limited ability to penetrate cell membranes, especially with lower blood-brain barrier penetration, which may reduce the risk of central nervous system-related side effects. The negative and genotoxic results of hERG inhibitory results indicate good safety and suitability for further drug development.
Currently, pharmacokinetic (PK) data on Multicaulisin are relatively scarce. Future studies are needed to systematically study its absorption, distribution, metabolism, and excretion (ADME) characteristics to clarify its in vivo half-life, metabolic pathways, and potential drug interactions. Considering its high lipid solubility and poor water solubility, it may be necessary to enhance bioavailability and targeting through pharmaceutical improvements (such as nanocarriers and liposomes).
Multicaulisin, as a novel natural Diels-Alder additive, demonstrates significant anti-MRSA activity and multi-target anti-inflammatory effects, showing potential as a new anti-infective drug. Its unique structure and mechanism of action offer new ideas for overcoming traditional antibiotic resistance. In the future, Multicaulisin can serve as a candidate molecule for antimicrobial drugs, further optimizing its structure and enhancing efficacy and pharmacokinetic performance.
Additionally, Multicaulisin's multi-target role in regulating inflammatory responses opens up possibilities for its application in inflammatory diseases such as chronic inflammation and immune-mediated diseases. Combined with its safety advantages, Multicaulisin is expected to be developed as a therapeutic drug with dual anti-infective and anti-inflammatory functions.
However, the clinical translation of Multicaulisin still faces many challenges, including the improvement of large-scale preparation techniques, systematic pharmacokinetic and toxicological evaluation, preclinical animal model validation, and the design and implementation of clinical trials. Future research should focus on in-depth analysis of its mechanism of action, formulation development, and clarification of clinical indications, to promote its early entry into clinical application.
Multicaulisin, a newly discovered natural Diels-Alder additive in the roots of mulberry species, demonstrates broad drug development prospects due to its significant anti-MRSA activity and multi-target anti-inflammatory effects. Its unique chemical structure and excellent safety provide valuable resources for the development of new anti-infective drugs. Although its pharmacokinetics and clinical applications still require further research, Multicaulisin has become an important research hotspot in the field of natural product pharmacology. In the future, through multidisciplinary collaborative innovation, it is expected to transform from the laboratory to clinical practice, supporting the treatment of resistant infections and inflammatory diseases.
